Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: Preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD)

Health and Quality of Life Outcomes

Volumn 12, Issue 1, 2014, Pages

  Reddy, Prashanth ^a,f   Martinez Martin, Pablo ^b   Brown, Richard G ^c,f   Chaudhuri, Kallol R ^a,f   Lin, Jean Pierre ^d   Selway, Richard ^a,f   Forgacs, Ian ^a,f   Ashkan, Keyoumars ^a,f   Samuel, Michael ^a,e,f  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; ATTITUDE TO HEALTH; DEEP BRAIN STIMULATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT OUTCOME ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84892691935     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-12-11     Document Type: Article

References (28)

1. Forsaa EB, Larsen JP, Wentzel-Larsen T, Herlofson K, Alves G. Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord 2008, 23:1420-1427. 10.1002/mds.22121, 18512757.
2. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. Group NV The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011, 26:399-406. 10.1002/mds.23462, 21264941, Group NV.
3. Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M. Group P-PS Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson's disease?. Mov Disord 2012, 27:236-241. 10.1002/mds.23961, 21954027, Group P-PS.
4. Volkmann J, Albanese A, Antonini A, et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol 2013, 260:2701-2714. 10.1007/s00415-012-6798-6, 3825542, 23287972.
5. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the food and drug administration, february 16, 2001. Value Health 2003, 6:522-531. 10.1046/j.1524-4733.2003.65309.x, 14627058.
6. Martinez-Martin P, Rodriguez-Blazquez C, Frades-Payo B. Specific patient-reported outcome measures for Parkinson's disease: analysis and applications. Expert Rev Pharmacoecon Outcomes Res 2008, 8:401-418. 10.1586/14737167.8.4.401, 20528346.
7. Nisenzon AN, Robinson ME, Bowers D, Banou E, Malaty I, Okun MS. Measurement of patient-centered outcomes in parkinson: what do patients really want from their treatment?. Parkinsonism Relat Disord 2011, 17:89-94. 10.1016/j.parkreldis.2010.09.005, 3034811, 20952243.
8. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007, 22:41-47. 10.1002/mds.21198, 17115387.
9. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007, 22:1901-1911. 10.1002/mds.21596, 17674410.
10. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998, 245(Suppl 1):S10-14.
11. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
12. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's cognitive examination revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006, 21:1078-1085. 10.1002/gps.1610, 16977673.
13. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010, 9:581-591. 10.1016/S1474-4422(10)70093-4, 2874872, 20434403.
14. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006, 355:896-908. 10.1056/NEJMoa060281, 16943402.
15. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease?. J Neurol Neurosurg Psychiatry 2000, 69:308-312. 10.1136/jnnp.69.3.308, 1737100, 10945804.
16. Reich M, Chaudhuri K, Ashkan K, et al. Changes in the non-motor symptom scale in Parkinson's disease after deep brain stimulation. Basal Ganglia 2011, 1:131-133.
17. Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol 2012, 11:429-442. 10.1016/S1474-4422(12)70049-2, 22516078.
18. Agid Y, Schupbach M, Gargiulo M, et al. Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so?. J Neural Transm Suppl 2006, 70:409-14. 10.1007/978-3-211-45295-0_61, 17017560.
19. Hulse NAK, Costello A, Moriarty J, Clough C, Selway R, Samuel M. Deep brain stimulation (DBS) as a treatment option for Parkinson's disease and essential tremor in elderly patients. Mov Disord 2008, 23:S127.
20. Brown RG. Behavioural disorders, Parkinson's disease, and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002, 72:689. 10.1136/jnnp.72.6.689, 1737936, 12023406.
21. Selai C. Assessing quality of life in dementia. Med Care 2001, 39:753-755. 10.1097/00005650-200108000-00001, 11468494.
22. McCabe R, Saidi M, Priebe S. Patient-reported outcomes in schizophrenia. Br J Psychiatry Suppl 2007, 50:s21-28.
23. Edwards SG, Playford ED, Hobart JC, Thompson AJ. Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation. BMJ 2002, 324:1493. 10.1136/bmj.324.7352.1493, 116445, 12077034.
24. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006, 4:79. 1629006, 17034633, U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health.
25. Ponds RWHMV, Jolles J. Age-related changes in subjective cognitive functioning. Educ Gerontol 2000, 26:67-81.
26. Schupbach M, Gargiulo M, Welter ML, et al. Neurosurgery in parkinson disease: a distressed mind in a repaired body?. Neurology 2006, 66:1811-1816. 10.1212/01.wnl.0000234880.51322.16, 16801642.
27. Hurt CS, Burn DJ, Hindle J, Samuel M, Wilson K, Brown RG. Thinking positively about chronic illness: an exploration of optimism, illness perceptions and well-being in patients with Parkinson's disease. Br J Health Psychol 2013, [Epub ahead of print].
28. De Ridder DT, Schreurs KM, Bensing JM. Adaptive tasks, coping and quality of life of chronically ill patients: the cases of Parkinson's disease and chronic fatigue syndrome. J Health Psychol 1998, 3:87-101. 10.1177/135910539800300107, 22021345.